Estêvão Lanna Figueiredo

ORCID: 0000-0001-5420-2482
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Atrial Fibrillation Management and Outcomes
  • Heart Failure Treatment and Management
  • COVID-19 Clinical Research Studies
  • Cardiac Arrhythmias and Treatments
  • Long-Term Effects of COVID-19
  • Venous Thromboembolism Diagnosis and Management
  • Cardiac electrophysiology and arrhythmias
  • Cardiovascular Function and Risk Factors
  • Cardiac pacing and defibrillation studies
  • Public Health in Brazil
  • Coronary Interventions and Diagnostics
  • Cardiac Imaging and Diagnostics
  • Health Systems, Economic Evaluations, Quality of Life
  • Acute Myocardial Infarction Research
  • Acute Ischemic Stroke Management
  • Cardiac, Anesthesia and Surgical Outcomes
  • Mechanical Circulatory Support Devices
  • Blood transfusion and management
  • SARS-CoV-2 and COVID-19 Research
  • Chronic Kidney Disease and Diabetes
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Erythropoietin and Anemia Treatment
  • Renal and Vascular Pathologies
  • Blood Pressure and Hypertension Studies

Centro Universitário de Belo Horizonte
2025

Lifecenter Hospital
2010-2023

Weatherford College
2023

Parallax Research (United States)
2021

Sir Ganga Ram Hospital
2018

KLE Society Hospital
2018

Duke Medical Center
2016

Universidade Federal de Minas Gerais
2005-2014

Faculdade de Ciências Médicas de Minas Gerais
2006

Unidades Centrales Científico-Técnicas
2005

Parte 1: Diretriz Brasileira de Insuficiencia Cardiaca Cronica […] e Aguda

10.5935/abc.20180190 article PT cc-by-nc Arquivos Brasileiros de Cardiologia 2018-01-01
Burkert Pieske Rolf Wachter Sanjiv J. Shah Abigail S. Baldridge Peter Szeczoedy and 95 more Ghionul Ibram Victor Shi Ziqiang Zhao Martín Cowie Aldo Carlos Prado Liza Maria Marcela Wenetz Daniela García Brasca Juan Pablo Albisu Alberto Alfredo Fernandez Alberto Liberman Graciela Echeverria Ines Bartolacci Maria Ranz Mercela Pedrotti Daniela Tapía Marina Robertson Solana Exposito Marcelo Barrionuevo Jorge Hector Resk Guillermo Mercau Ricardo León de la Fuente Horacio Avaca Carlos Poy Miguel Hominal Guillermo Cursack Oscar Ariel Vogelmann Marcelo Martín Casas Marcelo Costantino Josefina Chiriffe Robert Zweiker Lukas J. Motloch Johann Auer Peter Siostrzonek Wilhelm Grander David Derthoo Wilfried Müllens Hans Vandekerckhove Rachid Maamar Marc Delforge Tom Mulleners Salvador Rassi Adrian Kormann Aline Moraes Euler Roberto Fernandes Manenti Gilmar Reis Lília Nigro Maia Marcus Vinı́cius Simões Ricardo Pereira Silva Luiz Cláudio Danzmann José Francisco Kerr Saraiva Maria Christiane Valéria Braga Braile-Sternieri Weimar sebba Barroso de Souza Estêvão Lanna Figueiredo M. Tzekova Boryana Boeva Dimo Vasilev Snezhanka Tomova Tisheva Gospodinova Maria Milanova Valentina Mincheva Kabakchieva Petkana Ivanova Valchanova Bojidar I Dimov Plamen Dimitrov Petrovsky P Georgiev N Spasova Georgi Mazhdrakov Mariana Konteva Haralambi O Benov Stefan Vesselinov Denchev Marie Parent Catherine Demers Danielle Dion Ronald Bourgeois M Heffernan GUSTAVO ADOLFO MORENO SILGADO Franklin Quiroz Alberto Cadena J.L. Mendoza Clara Saldarriaga Camilo Arana Libor Nechvátal Kateřina Linhartová Zdeněk Klimsa Ladislav Busak Dan Marek Josef Slaby Rostislav Polášek Pavel Koleckar Jiri Carda Marta Kaislerova Pavel Trestik Petr Zajíček Jiří Kuchař Jiří Vondrák J Krupicka Tomáš Brychta

<h3>Importance</h3> There is limited evidence on the benefits of sacubitril/valsartan vs broader renin angiotensin system inhibitor background therapy surrogate outcome markers, 6-minute walk distance, and quality life in patients with heart failure mildly reduced or preserved left ventricular ejection fraction (LVEF &gt;40%). <h3>Objective</h3> To evaluate effect N-terminal pro–brain natriuretic peptide (NT-proBNP) levels, medication–based individualized comparators chronic LVEF more than...

10.1001/jama.2021.18463 article EN JAMA 2021-11-16
Zelalem Temesgen Charles D. Burger Jason Baker Christopher Polk Claudia R. Libertin and 95 more Colleen F. Kelley Vincent C. Marconi Robert Orenstein Victoria M. Catterson William S. Aronstein Cameron Durrant Dale Chappell Omar Ahmed Gabrielle Chappell Andrew D. Badley Meghan Lewis Linda Sher Michael E. Bowdish Noah Wald‐Dickler Subarna Biswas L.C.W. Lam Khang Chung Ngoc Vo R Poblete May M. Lee Douglass Hutcheon Roberto L. Patron John Gharbin Caitlin A. Moran Sheetal Kandiah Valeria D. Cantos Paulina A. Rebolledo Carlos del Río Jeffrey L. Lennox Carmen Polito Anandi N. Sheth Anup Patel Homero Paniagua Seife Yohannes Alpesh Amin Richard Lee Miki Watanabe Lanny Hsieh Martin Cearras Amay Parikh Jason Sniffen Wilfred Onyia Michael S Boger Lisa Davidson Kiran Gajurel Michael Leonard Lewis McCurdy Nestor Quezada Mindy Sampson Zainab Shahid Stephanie Strollo David Weinrib Sara Zulfigar Cheryl McDonald John Hollingsworth John R. Burk Joshua Berg D Barbaro Andrew C. Miller Lakshmi Sambathkumar Stuart McDonald Obinna Okoye Juan D Pulido Jennifer C. Fulton William B. Gill Richard A. Zuckerman Lionel D. Lewis Chaitanya Mandapakala Matthew K. Robinson Brian S Metzger Maqsood Alam Chrisoula Politis Anne Frosch Linh Ngo Fernando Carvalho Neuenschwander Estêvão Lanna Figueiredo Gualter CanÇado Gustavo Gomes de Araújo Lucas Melo Guimarães Ricardo Sobhie Diaz Natalia Bacellar Celso H. L. Silva Paulo Roberto Abrão Ferreira Marina Andrade Lima Caroline Uber Ghisi Camila Anton Ricardo Albaneze Daniel Wagner de Castro Lima Santos Ana Caroline Coutinho Iglessias Marianna M. Lago Paula Pietrobom Maysa B. Alves Juvencio Furtado Leopoldo Tosi Trevelin Valéria Telles Francini Guerra Correa

10.1016/s2213-2600(21)00494-x article EN other-oa The Lancet Respiratory Medicine 2021-12-02

BACKGROUND: Blood transfusion may precipitate adverse outcomes, including heart failure (HF), among patients with acute myocardial infarction (MI). This study characterizes the effects of a restrictive or liberal strategy on outcomes in MI and anemia without baseline HF. METHODS: In MINT trial (Myocardial Ischemia Transfusion), 3504 (hemoglobin &lt;10 g/dL) were randomized to &lt;8 strategy. We compared The primary outcome was death HF at 30 days. RESULTS: Compared (n=1633), those (n=1871)...

10.1161/circheartfailure.124.012495 article EN Circulation Heart Failure 2025-03-26

Introdução A última Diretriz de Insuficiência Cardíaca do Departamento da Sociedade Brasileira Cardiologia (DEIC/SBC) foi finalizada em março 2018. partir então, houve um importante número intervenções terapêuticas e abordagens diagnósticas que surgiram ou se consolidaram na prática clínica internacional pesquisa clínica. Ao lado disso, a pandemia COVID-19 trouxe-nos conhecimento sobre o modelo fisiopatológico agressão miocárdica muitas dúvidas acerca continuidade segurança dos medicamentos...

10.36660/abc.20210367 article PT cc-by-nc Arquivos Brasileiros de Cardiologia 2021-01-01

Atrial fibrillation (AF), the most common arrhythmia in clinical practice, is associated with an increase mortality and morbidity due to its high potential cause stroke systemic thromboembolism. Inflammatory mechanisms may play a role pathogenesis of AF maintenance. We aimed evaluate range inflammatory markers as potentially involved pathophysiology individuals nonvalvular (NVAF). A total 105 subjects were enrolled divided into two groups: patients NVAF (n = 55, mean age 72 ± 8 years)...

10.3390/ijms24043326 article EN International Journal of Molecular Sciences 2023-02-07

Introduction Viral infection by SARS-CoV2 is a pandemic affecting over 600 million people worldwide. One of five hospitalized patients may present myocardial injury, strongly associated with disease severity and mortality. Methodology Retrospective cross-sectional study COVID-19 diagnosed between May 01, 2020, June 30, 2021, from the database Registro Latinoamericano de Enfermedad Cardiovascular y (CARDIO COVID 19–20) troponin value recorded during hospitalization. A descriptive analysis...

10.3389/fcvm.2025.1545142 article EN cc-by Frontiers in Cardiovascular Medicine 2025-02-17

The inflammatory response associated with COVID-19 varies sex, potentially affecting disease outcomes. Males have a higher risk of complications compared to females, requiring an evaluation differences in severity based on sex. To compare clinical data, biochemical biomarkers, and outcomes among hospitalized patients Latin America the Caribbean (LA&C) sex perform cluster analysis biomarker profiles for both sexes. This prospective, multicenter observational registry made by Inter-American...

10.1186/s12872-025-04565-3 article EN cc-by-nc-nd BMC Cardiovascular Disorders 2025-03-05

Background: Atrial fibrillation (AF) is the most common arrhythmia associated with high risk of venous thrombo-embolism. Inflammatory mechanisms may be involved in pathophysiology AF and AF-related thrombogenesis. There no strong evidence showing whether use different oral anticoagulants present differences inflammatory profile patients AF. Hence, this study aimed to compare plasma levels markers individuals treated either warfarin or rivaroxaban. Methods: A total 127 subjects were included,...

10.3389/fcvm.2020.00114 article EN cc-by Frontiers in Cardiovascular Medicine 2020-07-24

Preeclampsia is an obstetric disease of unknown cause that affects approximately 5% pregnant women. The visual system may be affected with variable intensity, being the retinal detachment a rare complication. in preeclampsia usually bilateral and serous, its pathogenesis related to choroidal ischemia secondary intense arteriolar vasospasm. majority patients have complete recovery vision clinical management, surgery unnecessary. This case report 27 year old patient who developed severe form...

10.1590/s0066-782x2002001100011 article EN cc-by-nc Arquivos Brasileiros de Cardiologia 2002-08-01

The American Diabetes Association and the National Kidney Foundation define microalbuminuria as an albumin (μg)/creatinine (mg) ratio (ACR) between 30 300 μg/mg regardless of sex. Microalbuminuria is associated with increased cardiovascular risk. authors evaluated prevalence in nondiabetic nonhypertensive systolic heart failure (SHF) patients. Twenty‐seven SHF patients, 18 years older, New York Heart functional classes II through IV left ventricular ejection fraction ≤40%, who were not...

10.1111/j.1751-7133.2008.00008.x article EN Congestive Heart Failure 2008-09-01

Resumo Fundamento Na prática clínica, há evidências de falhas na prescrição terapias baseadas em para pacientes alto risco cardiovascular. Entretanto, no Brasil, ainda são insuficientes os dados sobre a evolução ao longo 1 ano desses pacientes. Objetivos Descrição acompanhamento 12 meses da utilização evidência e ocorrência desfechos cardiovasculares maiores seus principais preditores um registro brasileiro multicêntrico Métodos Estudo observacional prospectivo [...]

10.36660/abc.20190885 article PT Arquivos Brasileiros de Cardiologia 2020-12-07

Background Traditionally, the most effective therapy in prevention of stroke patients with atrial fibrillation (AF) has been oral anticoagulation vitamin K inhibitors, particularly warfarin, whose disadvantages and adverse effects have led to their replacement by “direct anticoagulants”, as factor X inhibitor. Objectives This study aimed conduct a brief approach on use Rivaroxaban, comparatively evaluate prothrombin time / International Normalized Ratio (PT/INR) AF [...]

10.36660/ijcs.20190141 article EN cc-by International Journal of Cardiovascular Sciences 2020-10-30

This observational, cross-sectional study based aimed to test whether heart failure (HF)-disease management program (DMP) components are influencing care and clinical decision-making in Brazil.The survey respondents were cardiologists recommended by experts the field invited participate via printed form or email. The consisted of 29 questions addressing site demographics, public versus private infrastructure, HF baseline data patients, HF, performance indicators, perceptions about...

10.6061/clinics/2021/e1991 article EN cc-by Clinics 2021-01-01

Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI

10.2139/ssrn.4789032 preprint EN 2024-01-01

While COVID-19 vaccination has been shown to reduce the risk of severe illness, its impact on occurrence persistent symptoms in patients with mild Omicron infection remains uncertain. Our objective was investigate whether reduces COVID-19-related 3 months after infection.

10.1016/j.jvacx.2024.100579 article EN cc-by-nc-nd Vaccine X 2024-11-04
Coming Soon ...